- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 21.10. | Lake Street Capital Markets initiates Genelux stock with Buy rating | 2 | Investing.com | ||
| 03.09. | GENELUX Corp - 8-K, Current Report | 5 | SEC Filings | ||
| 08.08. | Genelux GAAP EPS of -$0.20 beats by $0.02 | 2 | Seeking Alpha | ||
| 07.08. | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 07.08. | Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates | 94 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter... ► Artikel lesen | |
| 23.07. | Genelux stock maintains Buy rating at H.C. Wainwright amid sector news | - | Investing.com | ||
| 23.07. | Genelux: H.C. Wainwright bestätigt Kaufempfehlung trotz Rückschlag bei Konkurrenz | 1 | Investing.com Deutsch | ||
| 21.07. | Lucid Capital Markets initiates Genelux stock with Buy rating, $10 target | 1 | Investing.com | ||
| 07.07. | Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development | 179 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General... ► Artikel lesen | |
| 07.05. | Genelux GAAP EPS of -$0.21 | 1 | Seeking Alpha | ||
| 06.05. | Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates | 143 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter... ► Artikel lesen | |
| 28.03. | Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 182 | GlobeNewswire (Europe) | - Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer - - Positive Preliminary Phase 1b/2... ► Artikel lesen | |
| 25.03. | Genelux Corporation: Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer | 539 | GlobeNewswire (Europe) | - Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced... ► Artikel lesen | |
| 03.02. | Genelux Corporation Announces New Chief Financial Officer | 183 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 1,247 | -1,27 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,320 | -2,22 % | RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen | |
| IMMUNIC | 0,680 | +0,30 % | EQS-News: Immunic AG: Immunic to Participate in Industry and Investor Conferences in November | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Industry and Investor Conferences in November
29.10.2025 / 11:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| CURIS | 1,300 | +0,78 % | Curis, Inc.: Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | LEXINGTON, Mass., Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,742 | +0,11 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| ESPERION | 2,499 | -2,42 % | Esperion Therapeutics, Inc.: Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025 | ||
| KARYOPHARM | 5,300 | +3,92 % | Karyopharm Therapeutics Earnings Preview | ||
| CYBIN | 6,400 | +1,59 % | Cybin Inc (2): Cybin closes $175-million (U.S.) offering | ||
| BIOLINERX | 2,730 | 0,00 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,020 | 0,00 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics to Present at Investor Summit Virtual | CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization... ► Artikel lesen | |
| EDESA BIOTECH | 1,650 | +5,10 % | Edesa Biotech, Inc.: Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study | Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and... ► Artikel lesen | |
| BRIACELL THERAPEUTICS | 9,800 | +2,62 % | BriaCell Therapeutics Corp.: BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer | Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT plus immune check point inhibitorFourth consecutive positive DSMB recommendation... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 7,400 | +1,37 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination | Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated... ► Artikel lesen | |
| CINGULATE | 3,800 | +4,97 % | Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights | Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 3,100 | -1,27 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH in the European Union | - EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval... ► Artikel lesen |
Das Unternehmen GENELUX CORPORATION kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,13 % bei einem Aktienkurs von 8,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.